Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-26
2006-12-26
Morris, Patricia L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S272700, C546S275100
Reexamination Certificate
active
07153874
ABSTRACT:
The present invention provides 4-[1-Aryl-imidazol-4-ylethynyl]-2-alkyl-pyridine and 1-heteroaryl-imidazol-4-ylethynyl]-2-alkyl-pyridine derivatives and pharmaceutically acceptable salts thereof for the treatment or prevention of disorders mediated in full or in part by metabotropic glutamate receptor 5. These disorders include, e.g. acute, traumatic and chronic degenerative processes of the nervous system, such as Alzheimer's disease, senile dementia, Parkinson's disease, Huntington's chorea, amyotrophic lateral sclerosis and multiple sclerosis, psychiatric diseases, such as schizophrenia and anxiety, depression, pain and drug dependency.
REFERENCES:
patent: 3303199 (1967-02-01), Doebel et al.
patent: 3341548 (1967-09-01), Hoffer
patent: 4352818 (1982-10-01), Hunkeler et al.
patent: 4711962 (1987-12-01), Leone-Bay
patent: 2004/0259917 (2004-12-01), Cosford et al.
patent: 2035905 (1972-02-01), None
patent: 059 390 (1982-09-01), None
patent: 0 304 910 (1989-03-01), None
patent: WO 91/00277 (1991-01-01), None
patent: WO 99/02497 (1999-01-01), None
patent: WO 99/08678 (1999-02-01), None
patent: WO 01/16121 (2001-03-01), None
patent: WO 02/46166 (2002-06-01), None
Sakamoto et al., Chem. Pharm. Bull., vol. 35(2) pp. 823-828 (1987).
Miller, et al., Chem. Mater., vol. 6(7) pp. 1023-1032 (1994).
Rapoport et al., Environ. Health Perspect. vol. 67, pp. 41-45 (1986).
Bond et al., Synth. Commun., vol. 19, pp. 2551-2566 (1989).
Sintas et al., Journal of Labelled Compds. & Radiopharmaceuticals, vol. 39, pp. 677-684 (1997).
Hoffer et al., J. Med. Chem., vol. 17(9) pp. 1019-1020 (1974).
Ohba et al. Chem. Pharm. Bull. vol. 42, pp. 1784-1790 (1994).
Kulkarni et al., Aust. J. Chem. vol. 40(8) pp. 1399-1413 (1987).
Vasileuskii et al., Bull. Acad. Sci. USSR Div. Chem. Sci. pp. 626-628 (1983).
Laronde et al., Inorg. Chim. Acta, vol. 296(1), pp. 208-221 (1999).
Shafiee et al., J. Heterocyclic Chem. vol. 33, pp. 671-673 (1996).
Shafiee et al., J. Heterocyclic Chem. vol. 35, pp. 607-610 (1998).
Ivanova et al. Chem. Heterocycl. Comp. vol. 36(2), pp. 262-264 (2000).
Wadsworth, G. H., J. Chem. Soc. vol. 57, p. 11 (1890).
Cornforth & Cookson, J. Chem. Soc. pp. 1085-1087 (1952).
Ross et al., J. Med. Chem. vol. 15(10) pp. 1035-1040 (1972).
Mutel, V., Expert Opin. Ther. Patents 12:12 (2002).
Kiyomori et al., Tetrahedron Lett. vol. 40: p. 2657-2660 (1999).
Tohda et al., Synthesis p. 777-778 (1977).
Cliff et al., Synthesis pp. 681-682 (1994).
Ohira, Synth. Comm. 19: pp. 561-564 (1989).
Collman et al., Org. Lett. 2: p. 1233-1236 (2000).
Schlaeger & Christensen, Cytotechnology 30:71-83 (1999).
Porter et al., Br. J. Pharmacol. 128: pp. 13-20 (1999).
Millan, Progress in Neurobiology 70: pp. 83-244 (2003).
Abstract corresponding to DE 2035905 (Document B6 above).
Arena, F. et al., Journal of Medicinal Chemistry, vol. 18, No. 11, pp. 1147-1150 (1975).
Buettelmann Bernd
Ceccarelli Simona Maria
Jaeschke Georg
Kolczewski Sabine
Porter Richard Hugh Philip
Hoffmann-La Roche Inc.
Johnston George W.
Morris Patricia L.
Prior Kimberly J.
Rocha-Tramaloni Patricia S.
LandOfFree
Imidazole derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazole derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazole derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3711603